Other retrospectivestudies with GLP-1RA use in T1DM showed similar findings of reductions in HbA1c,weight, and insulin dose, although the number of patients in those studies weresimilarly small (11 patients in 1 study and 27 in the other).21,22 Mostrecently, Edwards et al. 16 published data on real-world use of SGLT2i and GLP-1RA, this study reportedon the largest real-world cohort of GLP-1RA use in T1DM. The gene discussed is INS; the disease is type 1 diabetes mellitus.